Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 716

1.

Concurrent mycosis fungoides and intravascular large B-cell lymphoma in a single patient.

Goyal A, Totoratis K, Toama W, He F, Bohjanen K, Williams S, Miller DD.

J Cutan Pathol. 2020 Feb 22. doi: 10.1111/cup.13669. [Epub ahead of print]

PMID:
32087036
2.

Presence of human papillomavirus DNA in voriconazole-associated cutaneous squamous cell carcinoma.

Nguyen CV, He Q, Rady PL, Tyring SK, Miller DD, Rubin N, Kovarik CL.

Int J Dermatol. 2020 Feb 14. doi: 10.1111/ijd.14820. [Epub ahead of print]

PMID:
32060904
3.

Treatment of Childhood-Onset Lupus Erythematosus Panniculitis With Rituximab.

Correll CK, Miller DD, Maguiness SM.

JAMA Dermatol. 2020 Feb 12. doi: 10.1001/jamadermatol.2019.4984. [Epub ahead of print]

PMID:
32049306
4.

Machine Intelligence in Cardiovascular Medicine.

Miller DD.

Cardiol Rev. 2020 Mar/Apr;28(2):53-64. doi: 10.1097/CRD.0000000000000294.

PMID:
32022759
5.

Machine Intelligence for Management of Acute Coronary Syndromes: Neural or Nervous Times?

Miller DD.

Can J Cardiol. 2019 Sep 20. pii: S0828-282X(19)31263-2. doi: 10.1016/j.cjca.2019.09.007. [Epub ahead of print] No abstract available.

PMID:
32007347
6.

Structure-Activity Relationship Study of Novel 6-Aryl-2-benzoyl-pyridines as Tubulin Polymerization Inhibitors with Potent Antiproliferative Properties.

Chen H, Deng S, Wang Y, Albadari N, Kumar G, Ma D, Li W, White SW, Miller DD, Li W.

J Med Chem. 2020 Jan 23;63(2):827-846. doi: 10.1021/acs.jmedchem.9b01815. Epub 2020 Jan 7.

PMID:
31860298
7.

VERU-111 suppresses tumor growth and metastatic phenotypes of cervical cancer cells through the activation of p53 signaling pathway.

Kashyap VK, Dan N, Chauhan N, Wang Q, Setua S, Nagesh PKB, Malik S, Batra V, Yallapu MM, Miller DD, Li W, Hafeez BB, Jaggi M, Chauhan SC.

Cancer Lett. 2020 Feb 1;470:64-74. doi: 10.1016/j.canlet.2019.11.035. Epub 2019 Dec 3.

PMID:
31809801
8.

X-ray Crystal Structure Guided Discovery and Antitumor Efficacy of Dihydroquinoxalinone as Potent Tubulin Polymerization Inhibitors.

Arnst KE, Banerjee S, Wang Y, Chen H, Li Y, Yang L, Li W, Miller DD, Li W.

ACS Chem Biol. 2019 Dec 20;14(12):2810-2821. doi: 10.1021/acschembio.9b00696. Epub 2019 Nov 25.

PMID:
31714738
9.

An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.

Deng S, Krutilina RI, Wang Q, Lin Z, Parke DN, Playa HC, Chen H, Miller DD, Seagroves TN, Li W.

Mol Cancer Ther. 2020 Feb;19(2):348-363. doi: 10.1158/1535-7163.MCT-19-0536. Epub 2019 Oct 23.

PMID:
31645441
10.

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.

Ponnusamy S, He Y, Hwang DJ, Thiyagarajan T, Houtman R, Bocharova V, Sumpter BG, Fernandez E, Johnson D, Du Z, Pfeffer LM, Getzenberg RH, McEwan IJ, Miller DD, Narayanan R.

Clin Cancer Res. 2019 Nov 15;25(22):6764-6780. doi: 10.1158/1078-0432.CCR-19-1458. Epub 2019 Sep 3.

PMID:
31481513
11.

The medical AI insurgency: what physicians must know about data to practice with intelligent machines.

Miller DD.

NPJ Digit Med. 2019 Jun 28;2:62. doi: 10.1038/s41746-019-0138-5. eCollection 2019. Review.

12.

Diffuse, mottled hyperpigmentation and mutations in LMNA gene in a 5-year-old boy, his mother, and his grandmother: Atypical progeroid syndrome.

Schultz B, Miller DD, Maguiness S.

Pediatr Dermatol. 2019 Nov;36(6):913-917. doi: 10.1111/pde.13917. Epub 2019 Aug 4.

PMID:
31378009
13.

Structure-Guided Design, Synthesis, and Biological Evaluation of (2-(1H-Indol-3-yl)-1H-imidazol-4-yl)(3,4,5-trimethoxyphenyl) Methanone (ABI-231) Analogues Targeting the Colchicine Binding Site in Tubulin.

Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, White SW, Miller DD, Li W, Li W.

J Med Chem. 2019 Jul 25;62(14):6734-6750. doi: 10.1021/acs.jmedchem.9b00706. Epub 2019 Jul 12.

PMID:
31251599
14.

Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.

Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.

Mol Pharmacol. 2019 Jul;96(1):73-89. doi: 10.1124/mol.118.114801. Epub 2019 May 1.

PMID:
31043459
15.

Addressing the Diversity-Validity Dilemma Using Situational Judgment Tests.

Juster FR, Baum RC, Zou C, Risucci D, Ly A, Reiter H, Miller DD, Dore KL.

Acad Med. 2019 Aug;94(8):1197-1203. doi: 10.1097/ACM.0000000000002769.

PMID:
31033603
16.

Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.

Khan N, Jajeh F, Eberhardt EL, Miller DD, Albrecht DM, Van Doorn R, Hruby MD, Maresh ME, Clipson L, Mukhtar H, Halberg RB.

Int J Cancer. 2019 Dec 1;145(11):3022-3032. doi: 10.1002/ijc.32367. Epub 2019 May 10.

PMID:
31018249
17.

Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer.

Yang R, Chen H, Guo D, Dong Y, Miller DD, Li W, Mahato RI.

J Pharmacol Exp Ther. 2019 Sep;370(3):864-875. doi: 10.1124/jpet.119.256628. Epub 2019 Apr 17.

PMID:
30996033
18.

Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10.

Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG.

JAMA Dermatol. 2019 Apr 1;155(4):448-454. doi: 10.1001/jamadermatol.2018.5605. Erratum in: JAMA Dermatol. 2019 Jul 31;:.

PMID:
30840032
19.

Recurrent corneal erosion: a comprehensive review.

Miller DD, Hasan SA, Simmons NL, Stewart MW.

Clin Ophthalmol. 2019 Feb 11;13:325-335. doi: 10.2147/OPTH.S157430. eCollection 2019. Review.

20.

Novel Use of Deoxycholic Acid for Adiposis Dolorosa (Dercum Disease).

Wipf A, Lofgreen S, Miller DD, Farah RS.

Dermatol Surg. 2019 Dec;45(12):1718-1720. doi: 10.1097/DSS.0000000000001800. No abstract available.

PMID:
30789509
21.

Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Arnst KE, Banerjee S, Chen H, Deng S, Hwang DJ, Li W, Miller DD.

Med Res Rev. 2019 Jul;39(4):1398-1426. doi: 10.1002/med.21568. Epub 2019 Feb 11. Review.

PMID:
30746734
22.

Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer.

Kashyap VK, Wang Q, Setua S, Nagesh PKB, Chauhan N, Kumari S, Chowdhury P, Miller DD, Yallapu MM, Li W, Jaggi M, Hafeez BB, Chauhan SC.

J Exp Clin Cancer Res. 2019 Jan 23;38(1):29. doi: 10.1186/s13046-018-1009-7.

23.

3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent.

Kerns JK, Busch-Petersen J, Fu W, Boehm JC, Nie H, Muratore M, Bullion A, Lin G, Li H, Davis R, Lin X, Lakdawala AS, Cousins R, Field R, Payne J, Miller DD, Bamborough P, Christopher JA, Baldwin I, Osborn RR, Yonchuk J, Webb E, Rumsey WL.

ACS Med Chem Lett. 2018 Oct 30;9(12):1164-1169. doi: 10.1021/acsmedchemlett.8b00291. eCollection 2018 Dec 13.

24.

New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.

Hwang DJ, He Y, Ponnusamy S, Mohler ML, Thiyagarajan T, McEwan IJ, Narayanan R, Miller DD.

J Med Chem. 2019 Jan 24;62(2):491-511. doi: 10.1021/acs.jmedchem.8b00973. Epub 2018 Dec 26.

PMID:
30525603
25.

How Cognitive Machines Can Augment Medical Imaging.

Miller DD, Brown EW.

AJR Am J Roentgenol. 2019 Jan;212(1):9-14. doi: 10.2214/AJR.18.19914. Epub 2018 Nov 13.

PMID:
30422716
26.

Display of Arms: A Roundtable Discussion about the Public Exhibition of Firearms and Their History.

Tucker J, Adamson G, Ferguson JS, Garrett-Davis J, Goldstein E, Hlebinsky A, Miller DD, Slavick S.

Technol Cult. 2018;59(3):719-769. doi: 10.1353/tech.2018.0064. No abstract available.

PMID:
30245500
27.

Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.

Wang Q, Arnst KE, Wang Y, Kumar G, Ma D, Chen H, Wu Z, Yang J, White SW, Miller DD, Li W.

J Med Chem. 2018 Sep 13;61(17):7877-7891. doi: 10.1021/acs.jmedchem.8b00827. Epub 2018 Aug 30.

28.

Achieving sustainable and equitable fisheries requires nuanced policies not silver bullets.

Cisneros-Montemayor AM, Cashion T, Miller DD, Tai TC, Talloni-Álvarez N, Weiskel HW, Sumaila UR.

Nat Ecol Evol. 2018 Sep;2(9):1334. doi: 10.1038/s41559-018-0633-0. No abstract available.

PMID:
30038245
29.

The Big Health Data-Intelligent Machine Paradox.

Miller DD.

Am J Med. 2018 Nov;131(11):1272-1275. doi: 10.1016/j.amjmed.2018.05.038. Epub 2018 Jun 25. No abstract available.

PMID:
29953846
30.

Mycobacterium immunogenum folliculitis on the lower extremities of a healthy young adult.

McNeil EP, Goldfarb N, Hannon GR, Miller DD, Farah RS.

Clin Exp Dermatol. 2019 Apr;44(3):328-330. doi: 10.1111/ced.13703. Epub 2018 Jun 19. No abstract available.

PMID:
29920742
31.

Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States.

Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, Boggs J, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Gordon S, Hamrick R, Ho B, Hughey LC, Jones LM, Kaffenberger BH, Kindley K, Kroshinsky D, Kwong BY, Miller DD, Mostaghimi A, Musiek A, Ortega-Loayza AG, Patel R, Posligua A, Rani M, Saluja S, Sharon VR, Shinkai K, John JS, Strickland N, Summers EM, Sun N, Wanat KA, Wetter DA, Worswick S, Yang C, Margolis DJ, Gelfand JM, Rosenbach M.

J Invest Dermatol. 2018 Nov;138(11):2315-2321. doi: 10.1016/j.jid.2018.04.027. Epub 2018 Jul 27. Erratum in: J Invest Dermatol. 2019 Feb;139(2):495-496.

32.

Computationally identified novel agonists for GPRC6A.

Pi M, Kapoor K, Ye R, Hwang DJ, Miller DD, Smith JC, Baudry J, Quarles LD.

PLoS One. 2018 Apr 23;13(4):e0195980. doi: 10.1371/journal.pone.0195980. eCollection 2018.

33.

Synthesis and biological evaluation of indole-based UC-112 analogs as potent and selective survivin inhibitors.

Wang Q, Arnst KE, Xue Y, Lei ZN, Ma D, Chen ZS, Miller DD, Li W.

Eur J Med Chem. 2018 Apr 10;149:211-224. doi: 10.1016/j.ejmech.2018.02.045. Epub 2018 Feb 19.

34.

Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.

Banerjee S, Arnst KE, Wang Y, Kumar G, Deng S, Yang L, Li GB, Yang J, White SW, Li W, Miller DD.

J Med Chem. 2018 Feb 22;61(4):1704-1718. doi: 10.1021/acs.jmedchem.7b01858. Epub 2018 Feb 12.

35.

Investigation of 20S-hydroxyvitamin D3 analogs and their 1α-OH derivatives as potent vitamin D receptor agonists with anti-inflammatory activities.

Lin Z, Marepally SR, Goh ESY, Cheng CYS, Janjetovic Z, Kim TK, Miller DD, Postlethwaite AE, Slominski AT, Tuckey RC, Peluso-Iltis C, Rochel N, Li W.

Sci Rep. 2018 Jan 24;8(1):1478. doi: 10.1038/s41598-018-19183-7.

36.

Destroying the androgen receptor (AR)-potential strategy to treat advanced prostate cancer.

Narayanan R, Ponnusamy S, Miller DD.

Oncoscience. 2017 Dec 28;4(11-12):175-177. doi: 10.18632/oncoscience.389. eCollection 2017 Nov. No abstract available.

37.

Asymptomatic pink plaque on the scapula.

Nguyen CV, Miller DD, Farah RS.

Cutis. 2017 Nov;100(5):E15-E17. No abstract available.

PMID:
29232430
38.

A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.

Arnst KE, Wang Y, Hwang DJ, Xue Y, Costello T, Hamilton D, Chen Q, Yang J, Park F, Dalton JT, Miller DD, Li W.

Cancer Res. 2018 Jan 1;78(1):265-277. doi: 10.1158/0008-5472.CAN-17-0577. Epub 2017 Nov 27.

39.

Artificial Intelligence in Medical Practice: The Question to the Answer?

Miller DD, Brown EW.

Am J Med. 2018 Feb;131(2):129-133. doi: 10.1016/j.amjmed.2017.10.035. Epub 2017 Nov 7. Review.

PMID:
29126825
40.

Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer.

Ponnusamy S, Coss CC, Thiyagarajan T, Watts K, Hwang DJ, He Y, Selth LA, McEwan IJ, Duke CB, Pagadala J, Singh G, Wake RW, Ledbetter C, Tilley WD, Moldoveanu T, Dalton JT, Miller DD, Narayanan R.

Cancer Res. 2017 Nov 15;77(22):6282-6298. doi: 10.1158/0008-5472.CAN-17-0976. Epub 2017 Oct 4.

41.

Role of lysophosphatidic acid and its receptors in the kidney.

Park F, Miller DD.

Physiol Genomics. 2017 Nov 1;49(11):659-666. doi: 10.1152/physiolgenomics.00070.2017. Epub 2017 Sep 22. Review.

PMID:
28939644
42.

1α,20S-Dihydroxyvitamin D3 Interacts with Vitamin D Receptor: Crystal Structure and Route of Chemical Synthesis.

Lin Z, Chen H, Belorusova AY, Bollinger JC, Tang EKY, Janjetovic Z, Kim TK, Wu Z, Miller DD, Slominski AT, Postlethwaite AE, Tuckey RC, Rochel N, Li W.

Sci Rep. 2017 Aug 31;7(1):10193. doi: 10.1038/s41598-017-10917-7.

43.

The quinic acid derivative KZ-41 prevents glucose-induced caspase-3 activation in retinal endothelial cells through an IGF-1 receptor dependent mechanism.

He H, Weir RL, Toutounchian JJ, Pagadala J, Steinle JJ, Baudry J, Miller DD, Yates CR.

PLoS One. 2017 Aug 10;12(8):e0180808. doi: 10.1371/journal.pone.0180808. eCollection 2017.

44.

Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.

Chen H, Lin Z, Arnst KE, Miller DD, Li W.

Molecules. 2017 Aug 1;22(8). pii: E1281. doi: 10.3390/molecules22081281. Review.

45.

Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?

Pillai A, Schooler NR, Peter D, Looney SW, Goff DC, Kopelowicz A, Lauriello J, Manschreck T, Mendelowitz A, Miller DD, Severe JB, Wilson DR, Ames D, Bustillo J, Kane JM, Buckley PF.

Schizophr Res. 2018 Mar;193:263-268. doi: 10.1016/j.schres.2017.06.059. Epub 2017 Jul 19.

PMID:
28734907
46.

Adaptation strategies to climate change in marine systems.

Miller DD, Ota Y, Sumaila UR, Cisneros-Montemayor AM, Cheung WWL.

Glob Chang Biol. 2018 Jan;24(1):e1-e14. doi: 10.1111/gcb.13829. Epub 2017 Aug 17. Review.

PMID:
28727217
47.

The role of dermatopathology in inpatient care.

Nguyen CV, Miller DD.

Semin Cutan Med Surg. 2017 Mar;36(1):17-22. doi: https://doi.org/10.12788/j.sder.2017.013. Review.

PMID:
28247871
48.

Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma.

Yang R, Mondal G, Ness RA, Arnst K, Mundra V, Miller DD, Li W, Mahato RI.

J Control Release. 2017 Mar 10;249:32-41. doi: 10.1016/j.jconrel.2017.01.028. Epub 2017 Jan 24.

49.

Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.

Banerjee S, Norman DD, Lee SC, Parrill AL, Pham TC, Baker DL, Tigyi GJ, Miller DD.

J Med Chem. 2017 Feb 23;60(4):1309-1324. doi: 10.1021/acs.jmedchem.6b01270. Epub 2017 Feb 10.

PMID:
28112925
50.

An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.

Ponnusamy S, Tran QT, Thiyagarajan T, Miller DD, Bridges D, Narayanan R.

Exp Biol Med (Maywood). 2017 Mar;242(6):606-616. doi: 10.1177/1535370216688569. Epub 2017 Jan 16.

Supplemental Content

Loading ...
Support Center